NIOX Group plc is a company that specialises in the development, manufacture, and distribution of medical devices for the diagnosis and monitoring of asthma. Their flagship product, NIOX VERO®, is a non-invasive medical device that measures fractional exhaled nitric oxide (FeNO) levels in patients with asthma. NIOX VERO® provides accurate and reliable results, allowing healthcare professionals to make informed decisions about the diagnosis and management of asthma. It is easy to use, and can be used in a variety of settings, including clinics, hospitals, and primary care settings. The NIOX Group plc is committed to improving the lives of people with asthma and is dedicated to innovation and excellence in its products and services. NIOX® is also committed to offering additional training and support for healthcare professionals. Overall, NIOX Group plc is the global leader in FeNO testing, with a strong reputation for innovation and excellence in the development of medical devices for the diagnosis and management of asthma. With NIOX VERO®, healthcare professionals have a reliable and non-invasive tool to help them better diagnose and manage asthma. References: 1. Alving K et al. Validation of a new portable exhaled nitric oxide analyzer, NIOX VERO®: randomized studies in asthma. Pulm Ther. 2017;3:207-218. 2. Gao J et al. Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma. Allergy, Asthma & Clinical Immunology. 2018;1 3. Busse WW et al. Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. Lancet Respir Med. 2021;9(10):1165-1173. 4. Menzies-Gow A et al. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020;55(3):1901633. 5. NIOX®. Data on File; MKT-DOF-007.
View Top Employees from NIOX®Website | https://niox.com |
Ticker | CIR |
Revenue | $34.2 million |
Funding | $667.3 million |
Employees | 137 (137 on RocketReach) |
Founded | 2006 |
Phone | +44 1865 405560 |
Fax | +44 70 9298 7560 |
Technologies |
JavaScript,
HTML,
PHP
+41 more
(view full list)
|
Industry | Medical Devices, Medical Devices & Equipment, Biotechnology, Distributors/Wholesale, NIOX® asthma management, Manufacturing, Science and Engineering, Allergy Immunotherapy, Health Care, Asthma And Chronic Obstructive Pulmonary Disease Treatment, Pharmaceutical |
Web Rank | 4 Million |
Keywords | Respiratory Health |
Competitors | Amryt Pharma, DBV Technologies, Kite Pharma, Revance, UroGen Pharma (formerly TheraCoat) |
SIC | SIC Code 382 Companies, SIC Code 38 Companies |
NAICS | NAICS Code 334 Companies, NAICS Code 33 Companies |
Looking for a particular NIOX® employee's phone or email?
The NIOX® annual revenue was $34.2 million in 2024.
Samuel Isaacs is the Head of Marketing of NIOX®.
137 people are employed at NIOX®.
The NAICS codes for NIOX® are [334, 33].
The SIC codes for NIOX® are [382, 38].